Market Herald logo


Be the first with the news that moves the market
  • MGC Pharma has prescribed more than 600 patients to its CBD medicines across Australia and the U.K.
  • This is an increase of the 400 patients that were recorded at the end of September
  • An average of 19 prescriptions were issued per business day in October to date
  • MGC Pharma’s share price is up 5.88 per cent, with shares trading for 3.6 cents apiece

MGC Pharmaceuticals has prescribed more than 600 patients to its cannabinoid medicines in Australia and the U.K.

This is an increase from the total 400 patients that were recorded at the end of September, 2019.

In addition to this increase, a number of other patients are being treated with its CannEpil and MXP100 products globally via participation in ongoing clinical research.

CannEpil and MXP100 are both proprietary MGC Pharma products, that have been developed internally through its Research and Development division and have progressed through to commercialisation.

This is in line with MGC’s ‘Seed to Pharmacy’ strategy, with it owning all the intellectual property through each stage of the product’s development, from the genetics to the finished product.

CannEpil is a high CBD, low THC formula for epilepsy, while MXP100 is recommended for mild neurological disorders, inflammation, and hepatoma (liver cancer) patients.

The commercialisation of this portfolio of phytocannabinoid derived medicines is in line with its strategy in becoming a world-leading bio-pharma company through international distribution agreements.

MGC has appointed Grow Biotech PLC, a British headquartered company, for U.K. distribution.

Biotech specialises in developing revolutionary processes, practices, techniques, tools and formulations to bridge the gap between existing hemp medicines and accepted pharmaceutical standards.

It has also appointed IPS Specials, a company that manufacturers unlicensed compounded medications and formulations for community and hospital pharmacists and dispensing doctors.

Grow Biotech and IPS both provide direct official access into the U.K. medical hemp market with an extensive network of nearly 5500 pharmacies across the U.K.

In Australia, Health House International and Cannvalate were appointed as its regional distributors.

Health House International is an Australian-based specialist medicinal hemp company that sells and distributes medical hemp products to the community and hospital pharmacies.

Cannvalate is Australian’s largest network of hemp prescribers and dispensaries, 1000 doctors and 600 pharmacies, gives it quick and Australia wide access to patients across all specialties.

“The increased momentum of new prescriptions in Australia and the U.K. is a testament to the effectiveness of our phytocannabinoid medicines and growing recognition from, and use by, the medical community,” Managing Director Roby Zomer said.

“I believe that this is just the beginning of our market penetration and we will be able to sustain this attractive growth trajectory,” he added.

MGC Pharma’s share price is up 5.88 per cent, with shares trading for 3.6 cents apiece in a $46.46 million market cap.

MXC by the numbers
More From The Market Herald

" Alterity Therapeutics (ASX:ATH) expands clinical development program

Alterity Therapeutics (ATH) is expanding the phase two clinical development program for its lead asset ATH434 in patients with Multiple System Atrophy (MSA).
Althea Group (ASX:AGH) - CEO, Joshua Fegan

" Althea Group (ASX:AGH) hits new high in sales receipts

Althea Group (AGH) brought in a new high of $4.5 million in customer receipts over the recently completed September quarter.
Singular Health Group (ASX:SHG) - Chief Operating Officer, James Hill

" Singular Health (ASX:SHG) collaborates with CSIRO and Osteopore (ASX:OSX)

Singular Health Group (SHG) will collaborate with CSIRO and Osteopore (OSX) for an artificial intelligence (AI) based tool to make patient-specific 3D cranial
ImpediMed (ASX:IPD) - MD and CEO, Richard Carreon

" ImpediMed (ASX:IPD) completes lymphoedema prevention trial

ImpediMed (IPD) has rounded off its PREVENT trial, successfully meeting its primary end point.